GANZIMMUN Diagnostics
Healthcare Services · 51-200 Employees
View Company Info for Free
Overview
Phone Number
+49 613172050Website
www.ganzimmun.deRevenue
$25.6 MillionIndustry
About GANZIMMUN Diagnostics
Is GANZIMMUN Diagnostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at GANZIMMUN Diagnostics
Product Launch: Get notified when GANZIMMUN Diagnostics launches new products
Funding: Get notified immidiatlly once GANZIMMUN Diagnostics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if GANZIMMUN Diagnostics had a recent Job posting/layoffs
Check out if GANZIMMUN Diagnostics is spiking on competitors!
GANZIMMUN Diagnostics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on GANZIMMUN Diagnostics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if GANZIMMUN Diagnostics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at GANZIMMUN Diagnostics
Find 3 more new buyers
Company Profile Activity
Activity Insights
GANZIMMUN Diagnostics is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
GANZIMMUN Diagnostics is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about GANZIMMUN Diagnostics.
GANZIMMUN Diagnostics Tech Stack
A closer look at the technologies used by GANZIMMUN Diagnostics
GANZIMMUN Diagnostics News & Media
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlertMainz Biomed Expands ColoAlert Commercialization with GANZIMMUN Diagnostics in Europe
BERKELEY, Calif. and MAINZ, Germany, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with leading diagnostics laboratory GANZIMMUN Diagnostics AG (GD), one of Europe's leading laboratories for preventive and complementary medicine, for the commercialization in Germany of ColoAlert, Mainz’s unique, highly efficacious, and easy-to
Top Healthcare Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding GANZIMMUN Diagnostics
MVZ GANZIMMUN GmbH is a leading laboratory in Europe specializing in innovative diagnostics and personalized health solutions. They provide a comprehensive range of laboratory analyses based on modern technology and scientifically validated methods, supporting physicians, therapists, and patients. Their services include allergy testing, genetic dia... Read More